Balance scale with cancer cells and Imatinib molecules.

Imatinib and Secondary Cancers: What You Need to Know About This Leukemia Treatment

Lena Kashyap monogram
Lena Kashyap in Health & Wellness October 2026 • 4 min read.

"A deeper look at how Imatinib, a revolutionary treatment for chronic myeloid leukemia, might be linked to secondary malignancies."


Chronic myeloid leukemia (CML) is a type of cancer that starts in the bone marrow. For many years, the outlook for people with CML wasn't great, but then came a drug called Imatinib. Imatinib, also known as Gleevec, is a game-changer. It's a tyrosine kinase inhibitor, which means it targets specific proteins in cancer cells, helping to stop their growth. Because of Imatinib, people with CML can live longer, healthier lives.

Like any medication, Imatinib comes with its own set of considerations. Most side effects are mild, such as nausea or muscle cramps, but what about the long-term effects? That's where things get a little more complex. Recent studies and case reports have started to explore whether there's a connection between Imatinib and the development of secondary malignancies. These are new cancers that develop after someone has already been treated for CML.

In this article, we'll break down what the research says about Imatinib and secondary cancers. We'll look at the real numbers, explore different points of view from the experts, and give you clear, actionable information. Whether you're a patient, a family member, or just interested in learning more, this guide will help you understand the facts and make informed decisions about your health.

AI Search Multiple angles on this topic

Imatinib's Current Role

Imatinib, sold under the brand names Gleevec and Glivec, is an oral targeted therapy used to treat cancer. It is used for certain leukemias, bone marrow disorders, skin cancer, and some tumors of the stomach and digestive system. The National Cancer Institute provides information on imatinib mesylate, related research results, and ongoing clinical trials.

Treatment Considerations

Treatment decisions for imatinib-related conditions generally depend on the cancer or bone marrow disorder being treated and the medicines used alongside it. Because imatinib is an antineoplastic agent, its use requires clinical supervision and attention to potential limitations, including side effects and differences between individual conditions. The available information does not establish one universal treatment approach for every patient.

Development of Targeted Therapy

Imatinib represents the broader development of targeted medicines designed to act against cancer-related disease processes. Its place in leukemia treatment reflects progress beyond nonspecific cancer treatment, although the limited material provided here does not document specific discovery dates or milestones. Historical details should therefore be interpreted cautiously without additional source evidence.

Understanding Imatinib: How Does It Fight Leukemia?

Balance scale with cancer cells and Imatinib molecules.

To understand the discussion around Imatinib and secondary cancers, it's helpful to know how the drug actually works. Imatinib is designed to target a specific protein, called BCR-ABL, which is found in most CML cells. By blocking this protein, Imatinib helps to slow down or stop the growth of cancer cells.

Imatinib is generally considered safe, but it can cause side effects. Most of these are manageable, such as:

  • Nausea and Vomiting
  • Diarrhea
  • Muscle Cramps
  • Swelling (Edema)
  • Skin Rash
AI Search Multiple angles on this topic

Ongoing Imatinib Research

Research on imatinib continues to include clinical studies and evaluations of its use in cancer and bone marrow conditions. The available material indicates that ongoing clinical trials and research results are part of the evidence base surrounding imatinib. Specific recent findings or review conclusions are not established by the sources provided here.

Limits and Uncertainties

Imatinib is not a universal treatment for every cancer or blood disorder, and its use varies by diagnosis. Its benefits and limitations may differ depending on the condition, other medicines, and the patient's clinical circumstances. The provided sources do not supply specific failure rates, resistance figures, or competing criticisms.

Imatinib Versus Nilotinib

A randomized, open-label, multicenter trial compared imatinib mesylate with nilotinib in adults with newly diagnosed, cytogenetically confirmed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The trial was designed to determine the efficacy of imatinib mesylate versus nilotinib in this population. The provided source does not report the comparative results, so no conclusion about superiority can be drawn from it alone.

These side effects are usually mild and tend to decrease over time. However, some studies have raised questions about whether Imatinib might have other, more serious long-term effects. This is where the discussion about secondary malignancies comes in.

The Bottom Line: Weighing the Risks and Benefits

Imatinib has truly revolutionized the treatment of CML, turning what was once a deadly disease into a manageable condition. While the possibility of secondary cancers is a concern, it's important to keep things in perspective. The benefits of Imatinib in controlling CML are significant. Regular check-ups, open communication with your healthcare team, and a healthy lifestyle can all help you stay on top of your health.

AI Search Multiple angles on this topic

Putting Imatinib in Context

Imatinib is an oral targeted cancer therapy used across several cancer and bone marrow-related indications. Its role should be understood in relation to the specific diagnosis rather than as a single treatment for all leukemias or tumors. Clinical interpretation requires evidence about the individual condition, treatment plan, and potential risks.

The Continuing Research Landscape

Future progress in imatinib treatment may depend on continued research, clinical trials, and evaluation of how the medicine is used across different conditions. The available material confirms that ongoing studies remain part of the imatinib evidence base. It does not provide enough information to predict particular future indications, technologies, or outcomes.

Care Across Conditions

Imatinib is used in a broad clinical context that includes certain leukemias, bone marrow disorders, skin cancer, and tumors of the stomach and digestive system. This range of uses can make treatment decisions condition-specific rather than interchangeable. The sources provided do not address healthcare access, cost, or other systemic barriers.

Patient-Centered Treatment

For patients, imatinib treatment is shaped by the particular cancer or bone marrow condition being managed and by whether other medicines are used. Its oral form may be relevant to how treatment is administered, but the provided sources do not describe adherence, quality-of-life outcomes, or patient experiences. Individual decisions therefore require discussion with a qualified healthcare professional.

The reported patient and tumor

PopulationA 72-year-old woman with blastic phase of Philadelphia chromosome positive CML[1]
Main outcomeNeuroendocrine tumor with peritoneal carcinomatosis[1]
Times cited3[1]

How this report fits with other evidence

Separate imatinib-treated CML cohorts reported secondary malignancies in 5.8% after a median 74 months, 4.2% after 67.5 months, and 3.6% after a median 61 months; these cohort figures describe different follow-up periods and are not direct estimates from this case report.[2] [3] [4]

A review noted that speculation about increased urothelial cancer risk in a small imatinib cohort was not confirmed by a much larger study of 9,000 patients; that addresses a different malignancy question from the reported cecal tumor.[5]

Questions the evidence leaves open

  • Would the tumor have been detected at the same time without close follow-up?[1]
  • Can evidence from larger groups distinguish a possible imatinib effect from other factors associated with the patients and their care?[5]

Terms in the report

Tyrosine kinase inhibitor
A class of medicine that includes imatinib mesylate.[1]

Sources

  1. Neuroendocrine tumor of cecum in patient treated with imatinib mesylate for blastic phase of chronic myeloid leukemia (Informa UK Limited, 2017)
  2. Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia (pmc.ncbi.nlm.nih.gov)
  3. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV (pmc.ncbi.nlm.nih.gov)
  4. Occurrence of Secondary Malignancies in Chronic Myeloid Leukemia During Therapy with Imatinib Mesylate-Single Institution Experience (pmc.ncbi.nlm.nih.gov)
  5. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1080/17843286.2017.1316005, Alternate LINK

Title: Neuroendocrine Tumor Of Cecum In Patient Treated With Imatinib Mesylate For Blastic Phase Of Chronic Myeloid Leukemia

Subject: General Medicine

Journal: Acta Clinica Belgica

Publisher: Informa UK Limited

Authors: Sabina Novaković, Anamarija Kovač Peić, Hrvoje Holik, Božena Coha

Published: 2017-04-19

Everything You Need To Know

1

What is Imatinib, and how does it work against Chronic Myeloid Leukemia (CML)?

Imatinib, also known by the brand name Gleevec, is a tyrosine kinase inhibitor. It works by targeting a specific protein called BCR-ABL, which is prevalent in CML cells. By blocking BCR-ABL, Imatinib effectively slows or halts the growth of these cancerous cells, thus managing the disease. This targeted approach has significantly improved the prognosis for individuals with CML, turning a previously life-threatening condition into a more manageable one.

2

What are the known side effects of Imatinib?

Imatinib, while generally considered safe, can cause several side effects. Common and usually mild side effects include nausea, vomiting, diarrhea, muscle cramps, swelling (edema), and skin rash. These side effects typically diminish over time. It's crucial to discuss any side effects with your healthcare team to manage them effectively and ensure the best possible quality of life while on treatment.

3

Can Imatinib cause secondary cancers, and what does the research say?

Recent studies and case reports have begun to explore a potential link between Imatinib and the development of secondary malignancies. Secondary malignancies are new cancers that appear in patients who have already been treated for their primary cancer, in this case, CML. The research is ongoing, and the exact nature of the connection, if any, is still under investigation. It's essential for patients to discuss this potential risk with their healthcare providers to make informed decisions and undergo appropriate monitoring.

4

How has Imatinib changed the treatment landscape for Chronic Myeloid Leukemia (CML)?

Imatinib has revolutionized the treatment of CML. Before Imatinib, the outlook for people with CML was significantly less promising. Imatinib has transformed CML from a deadly disease into a manageable condition, allowing patients to live longer, healthier lives. It has set the stage for further advancements in targeted cancer therapies, offering hope and improved outcomes for many individuals diagnosed with CML.

5

What steps should a patient take if they are taking Imatinib to manage their health and potential risks?

Patients taking Imatinib should prioritize regular check-ups and maintain open communication with their healthcare team. This ensures that any potential side effects or long-term health concerns, including the possibility of secondary malignancies, are monitored and addressed promptly. Additionally, adopting a healthy lifestyle can further support overall health and well-being while undergoing treatment. It is crucial to weigh the significant benefits of Imatinib in managing CML against potential long-term risks and to make informed decisions in consultation with medical professionals.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.